C-myc expression in cell lines derived from chronic myeloid leukemia

Haematologica. 2004 Feb;89(2):241-3.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis / drug effects
  • Benzamides
  • Busulfan / pharmacology
  • Cell Division / drug effects
  • Cell Line, Tumor / drug effects
  • Cell Line, Tumor / metabolism
  • Gene Expression Regulation, Neoplastic / drug effects
  • Genes, myc*
  • Humans
  • Hydroxyurea / pharmacology
  • Imatinib Mesylate
  • Interferon-alpha / pharmacology
  • K562 Cells / drug effects
  • K562 Cells / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Neoplasm Proteins / biosynthesis*
  • Neoplasm Proteins / genetics
  • Piperazines / pharmacology
  • Proto-Oncogene Proteins c-myc / biosynthesis*
  • Pyrimidines / pharmacology

Substances

  • Antineoplastic Agents
  • Benzamides
  • Interferon-alpha
  • Neoplasm Proteins
  • Piperazines
  • Proto-Oncogene Proteins c-myc
  • Pyrimidines
  • Imatinib Mesylate
  • Busulfan
  • Hydroxyurea